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Objective: To evaluate the relationship between peripheral arterial disease and elevated levels of C-reactive protein in the
Japanese-Brazilian population of high cardiovascular risk. Methods: We conducted a cross-sectional study derived from a
population-based study on the prevalence of diabetes and associated diseases in the Japanese-Brazilian population. One thousand,
three hundred and thirty individuals aged e” 30 underwent clinical and laboratory examination, including measurement of
ultrasensitive C-reactive protein. The diagnosis of peripheral arterial disease was performed by calculating the ankle-brachial
index. We considered with peripheral arterial disease patients who had ankle-brachial index d” 0.9. After applying the exclusion
criteria, 1,038 subjects completed the study. Results: The mean age of the population was 56.8 years; 46% were male. The
prevalence of peripheral arterial disease was 21%, with no difference between genders. Data analysis showed no association
between peripheral arterial disease and ultrasensitive C-reactive protein. Patients with ankle-brachial index d” 0.70 showed
higher values   of ultrasensitive C-reactive protein and worse cardiometabolic profile. We found a positive independent association
of peripheral arterial disease with hypertension and smoking. Conclusion: The association between low levels of ankle-brachial
index and elevated levels of ultrasensitive C-reactive protein may suggest a relationship of gravity, aiding in the mapping of high-
risk patients.
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INTRODUCTION
Despite changes in lifestyle and the growing therapeuticarsenal, cardiovascular diseases remain the leading
cause of morbidity and mortality, especially in emerging
developed countries. Twenty-year data from the Ministry
of Health on the Health System showed that
cardiovascular diseases are the leading cause of death
in Brazil for both genders. In 2006, they accounted for
29.4% of deaths in the country, while neoplasia caused
15.1% 1.
Cardiovascular diseases arise by large from the
atherosclerotic process, so the study and understanding of
new risk factors for atherosclerosis are needed to identify
individuals at risk and also for the development of new
therapeutic strategies. Peripheral arterial atherosclerotic
disease is increasingly prevalent in modern society due in
part to the increase in life expectancy, affecting 202 million
people worldwide in 2010. During the last decade there
was a 28.7% increase in the prevalence of the disease in
countries of low and middle income per capita, and 13.1%
in high-income ones 2.
The pathophysiology of atherosclerosis is
complex and multifactorial. The initial change in this
process is endothelial dysfunction resulting from various
factors, such as hypertension, diabetes mellitus,
hypercholesterolemia, and smoking. During all phases of
the atherosclerotic process there is release of cytokines,
among them interleukin-6 (IL6), which is primarily
responsible for the hepatic stimulation for the release of
C-reactive protein (CRP), the main acute phase protein in
the inflammation process 3,4.
Thus, atherosclerosis is regarded as a dynamic
and progressive disease, arising from the combination of
endothelial dysfunction and inflammation. Endothelial
dysfunction is characterized by decreased production of nitric
oxide and increased expression of adhesion molecules.
These molecules promote the internalization of monocytes,
which transform into macrophages, releasing IL6, stimulating
the release of CRP, which in turn promotes the reduction
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of nitric oxide, stimulates the release of IL-6 and the
expression of endothelial adhesion molecules, perpetuating
the inflammatory response 3. CRP is currently considered
the main clinical marker of inflammation. Its involvement
in the atherosclerotic process has been discussed for
decades.
The relationship between CRP and cardiovascular
disease has been investigated mainly in the coronary
territory 5,6. Observational studies have consistently shown
that elevated CRP levels are associated with increased risk
for coronary heart disease and its dosage aids in the
prediction of disease 5,6. However, these studies provide
only limited and indirect information about the performance
of the marker in predicting disease 7.
Currently, there is great interest about the real
role of CRP in atherosclerosis: a causal factor or just a
mediator of disease? The association between CRP and
peripheral arterial disease (PAD) has been studied, however
so much less extensively than in the coronary field 8.
Our group conducted a population-based study on
the prevalence of diabetes mellitus and associated diseases in
Japanese immigrants and their descendants in Brazil. Japanese
populations of migrant origin have high rates of diabetes and
other cardiovascular risk factors 9. A high prevalence of chronic
diseases suggests that exposure to a different lifestyle
exacerbates a genetic tendency to accumulate fat, increasing
cardiovascular risk. These are genetically homogeneous
populations, with unfavorable cardiometabolic profile, which
contributes to the study of PAD and other complications of
atherosclerosis 10,11. Therefore, this population represents an
opportunity to investigate the relationship of PAD with new
risk factors, such as CRP.
METHODS
The study was conducted in the Japanese-
Brazilian population living in Bauru, São Paulo, Brazil. Male
and female individuals, aged e” 30 years were invited to
participate. Details on the recruitment and selection of
the sample population were previously described by the
authors 10,11.
The study was approved by the Ethics in Research
Committee of the Federal University of São Paulo, under
number 1544/10, and a free and informed consent was
obtained from all participants. One thousand, three hundred
and thirty participants were interviewed about clinical and
nutritional status and scheduled for clinical and laboratory
evaluation. Data on smoking and history of previous
diseases were obtained. The clinical examination included
anthropometric measures, blood pressure and ankle-brachial
index (ABI). Blood sample was obtained after 12 hours of
fasting for laboratory testing, including ultrasensitive C-
reactive protein (CRP). After applying the exclusion criteria
(incomplete data, CRP > 10mg/L and ABI > 1.40), 1,038
subjects completed the study.
Factors of conventional and non-conventional
risk: since the population is of Asian origin, we chose to
use the values   of Body mass index (BMI) recommended
by the Japan Society for the Study of Obesity (JASO) 12.
Values   of waist-hip ratio used were those recommended
by the World Health Organization (WHO) 13.
Hypertension was diagnosed in those who, during
the data collection, mentioned they have the disease and
were undergoing treatment, and in those who had, during
the physical examination, pressure values higher than
140x90mmHg 14. For the diagnosis of dyslipidemia, we used
the reference values recommended by the National
Cholesterol Education Program (NCEP) 15. We considered
diabetic patients who reported and were receiving drug
treatment for the disease, and those who were diagnosed
during the study according to the criteria of the American
Diabetes Association (ADA) 16.
Concentrations of uric acid up to 6mg/dL for
women and up to 7mg/dL for men were considered nor-
mal. The cutoff value for homocysteine was 15 mmol/L 17,
while for CRP, the one corresponding to the population
median value, which was 1.1 mg/L. Individuals with values
of CRP higher than 10mg/L were excluded. Glucose and
plasma lipoproteins were determined by enzymatic methods.
Concentrations of CRP were determined by
chemiluminescence.
The diagnosis of PAD was performed by using
an 8MHz continuous wave doppler device (Imbracios®).
The ABI was calculated as the quotient of auscultated
pressure in the arteries of the ankle by the highest pressure
obtained in the brachial arteries. As recommended by the
TASC II (Transatlantic Society Consensus) 18, we considered
abnormal a value d” 0.9 and> 1.40. We also stratified ABI
into three categories: d” 0.70, from 0.71 to 0.90 and>
0.90 19.
For the descriptive analysis, we used percentages,
mean and standard deviations of the subjects’ variables
grouped according to the presence of PAD or to the ABI
values (d” 0.70; 0.71 to 0.90; e” 0.90). We verified the
existence of associations between variables through the
use of chi-square and prevalence ratios (PR). For the
comparison of variables mean values, according to the
presence of PAD to the ABI values, we used the Student t
test or analysis of variance, respectively. We applied the
model of Poisson regression with robust variance in obtaining
the PR of PAD according to the CRP median. We adopted
a similar procedure to obtain the values of odds ratios
according to the ABI values (d” 0.70; from 0.71 to 0.90;
e” 0.90) and median CRP.
RESULTS
The mean age of the 1,038 Japanese-Brazilians
evaluated was 56.8 years; 46% were male. The mean
values of BMI, waist-hip ratio, blood pressure, fasting
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glucose, triglycerides, uric acid and homocysteine levels
were significantly higher in men. Total cholesterol, LDL-
cholesterol, HDL-cholesterol and CRP were significantly
higher in women.
Table 1 shows the prevalence of conventional
risk factors, CRP and homocysteine, in the population
studied. Especially among men, we observed a high
frequency of smoking (p < 0.01). Arterial hypertension did
not differ between genders. As for disorders of glucose
tolerance, the prevalence of DM was significantly higher
among men (38.7% versus 31.7%, p = 0.008), who also
more often presented hypertriglyceridemia, low HDL-
cholesterol, hyperuricemia and hyperhomocysteinemia.
Higher values of LDL-cholesterol and CRP were more
frequent in women.
The prevalence of PAD was 21.1% (n = 219),
with no difference between genders (19.2% vs. 22.7%),
and was higher in subjects aged e” 60 years with
hypertension and hyperhomocysteinemia. CRP was not
associated with PAD (Table 2). In the adjusted analysis, we
found a correlation between PAD and hypertension and
current smoking, and no relationship of PAD with CRP (Table
3). In ABI stratified analysis, we observed a relation between
PAD and hypertension and current smoking, and no
relationship of PAD with CRP (Table 4).
The analysis of the means, according to the
stratification of the ABI, showed higher mean CRP in patients
with ABI d” 0.70, but without statistical significance. Still,
the mean age of participants with ABI d” 0.70 was higher
than in other categories. The same occurred with the mean
fasting and two-hour glucose, homocysteine, systolic blood
pressure and number of cigarettes smoked per day (Table
5).
Furthermore, 70% of individuals with ABI d” 0.70
had diabetes mellitus and increased WHR values (Table 6).
DISCUSSION
We found a high prevalence of PAD (21.1%) in
this population of Japanese-Brazilians. Given that the
population presented unfavorable cardiometabolic profile,
this high prevalence was expected. Another study,
analyzing patients at high cardiovascular risk, found high
rates of PAD 20.
The risk factors independently associated with
PAD were smoking and hypertension in both genders.
CRP was not independently associated with PAD.
However, with the stratification of the ABI, we found
higher values of this variable in those with ABI d” 0.70,
but without statistical significance.   Nonetheless, this
subgroup of patients with ABI d” 0.70 was composed of
only 20 individuals, which makes the statistical analysis
difficult. Still, individuals with more advanced disease
Table 1 – Prevalence of the main cardiovascular risk factors in the Japanese-Brazilian population.
Var iable Gender p value
Ma le Female Total (n=1038)
(n=473) (n=565)
% % N %
Age >60 years 40.0 40.7 419 40.4 0.806
Smoking No 46.2 88.8 717 69.3 <0.001
Yes (past) 19.3 6.9 130 12.6
Yes (current) 34.5 4.3 187 18.1
Abdominal obesity 1 25.7 72.9 532 51.4 <0.001
Body mass index < 23 kg/m2 27.8 37.7 344 33.2 0.001
23.0 a 24.9 kg/m2 22.6 23.0 237 22.9
> 25 kg/m2 49.6 39.3 456 43.9
Arterial hypertension 47.2 43.9 471 45.4 0.295
Glucose tolerance Normal 3.4 7.5 58 5.6 0.008
GJA 35.9 36.7 377 36.4
TGD 22.0 24.1 240 23.1
DM 38.7 31.7 362 34.9
Hypercholesterolemia 60.0 64.1 646 62.2 0.182
Low HDL 16.5 9.0 129 12.4 <0.001
Increased LDL 43.1 52.7 502 48.4 0 .002
Hypertriglyceridemia 72.3 58.2 671 64.6 <0.001
CRP 1.1-9.9 46.7 54.5 529 51.0 0 .012
Homocysteine >15 mg/dL 22.7 7.8 119 14.5 <0.001
High uric acid 54.3 75.4 683 65.7 <0.001
1 WHR waist-hip ratio
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Table 2 – Number, percentage and prevalence ratios (PR) with respective 95% confidence intervals (95% CI) for Japanese-
Brazilians according to the presence of PAD and demographic, anthropometric, clinical and biochemical variables.
Var iable DAOP Chi-square P R 95%Ci
Yes N o Tota l
(n=219) (n=819) (n=1038)
% % N
Gender Female 22.7 77.3 565 1.80 1
Male 19.2 80.8 473 0.85 0.67-1.08
Age > 60 years 26.0 74.0 419 1 .46 1.16-1.85
Smoking Past 20.3 79.7 187 0.39 0.97 0.71-1.33
Current 23.1 76.9 130 1.10 0.78-1.56
Abdominal obesity (WHR) 1 22.0 78.0 532 0.57 1.10 0.86-1.39
Body mass index < 23 kg/m2 22.1 77.9 344 3.10 1
23.0 a 24.9 kg/m2 24.1 75.9 237 1.09 0.81-1.47
> 25 kg/m2 18.6 81.4 456 0.84 0.64-1.11
Hypertension 25.1 74.9 471 8 .1 1 .41 1.11-1.78
Glucose tolerance Normal 13.8 86.2 58 4.40 1
GJA 19.4 80.6 377 1.40 0.71-2.76
TGD 24.6 75.4 240 1.78 0.90-3.52
DM 21.8 78.1 362 1.58 0.81-3.10
Hypercholesterolemia 21.4 78.6 646 0.07 1.03 0.81-1.32
Low HDL 22.5 77.5 129 0.17 1.08 0.72-1.52
High LDL 21.3 78.7 502 0.03 1.02 0.81-1.29
Hypertriglyceridemia 21.3 78.7 671 0.05 1.03 0.80-1.32
 CRP 1.1-9.9 22.5 77.5 529 1.26 1.15 0.90-1.45
Homocysteine > 15 mg/dL 29.4 70.6 119 5 .36 1 .47 1.07-2.02
1 WHR waist-hip ratio.
Table 3 – Values of prevalence ratios (PR) with their respective 95%  confidence intervals (95% CI) for Japanese-Brazilians
according to the presence of PAD and other variables (final and initial model).
Var iable Initial model Final model
P R 95% Ci P R 95% Ci
CRP <1.1 1 1
1.1 – 9.9 1.00 0.73–1.38 1.03 0.76-1.39
Homocysteine <15 mg/dL 1 1
>15 mg/dL 1.25 0.88-1.77 1.26 0.89-1.78
Smoking No 1 1
Yes (past) 1.45 0.91-2.31 1.44 0.92-2.33
Yes (current) 2.14 1.32-3.50 2 .16 1.34-3.48
Age ? 60 years 1 1
> 60 years 0.98 0.71-1.36 0.94 0.69-1.23
Gender Female 1 1
Male 0.66 0.42-1.02 0.66 0.44-1.01
Arterial hypertension No 1 1
Yes 1.61 1.12-2.31 1 .56 1.12-2.22
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(ABI d” 0.70) were those with the worst cardiometabolic
profile, which can also interfere with CRP levels, a
phenomenon called reverse causality, ie, the
atherosclerotic plaque being a focus of inflammation,
observed changes in CRP values could reflect only the
inflammatory activity in the plate caused by other risk
factors 21. Elevated CRP levels may be secondary to several
Table 5 – Mean values   and standard deviation (SD) of demographic, anthropometric, clinical and biochemical variables of
Japanese-Brazilians according to the values   of the ankle-brachial index.
Var iable Ankle-brachial Index P
<0,70 0,71-0,90 >0,90 F-Stat ist ic
Mean (SD) Mean (SD) Mean (SD) (ANOVA)
Age (years) 65.1 (12.7) 59.3 (13.2) 56.0 (12.3) 10.14 < 0.001
Number of cigarettes per day * 22.5 (6.1) 17.9 (6.7) 17.3 (7.8) 1.99 0.141
WHR 0.91 (0.08) 0.87 (0.07) 0.88 (0.08) 3.06 0 .047
BMI (kg/m2) 25.2 (4.8) 24.4  (3.7) 24.9 (3.8) 1.34 0.263
DBP (mmHg) 85.2 (11.7) 79.7 (13.9) 79.1 (13.2) 2.09 0.125
SBP (mmHg) 151.3 (23.0) 137.6 (27.5) 131.2 (23.4) 9.86 < 0.001
Fasting blood glucose (mg/dl) * 148.0 (49.1) 120.5 (28.3) 124.9 (35.2) 6.56 0 .002
Two-hour glucose (mg/dl) * 239.2 (115.9) 164.1 (70.4) 162.2 (77.0) 7.45 0 .001
Total cholesterol (mg/dl) 209.3 (31.2) 214.3 (40.8) 214.8 (43.1) 0.17 0.840
HDL (mg/dl) * 49.5 (10.8) 50.4 (10.2) 51.4 (11.7) 0.65 0.523
LDL cholesterol (mg/dl) 126.1 (26.5) 130.0 (38.8) 130.6 (38.1) 0.15 0.864
Triglycerides (mg/dl) * 282.0 (226.1) 227.3 (185.1) 231.4 (199.7) 1.09 0.336
CRP * (mg/L) 2.1 (2.3) 1.8 (1.6) 1.8 (1.8) 0.21 0.813
Homocysteine * 12.3 (5.8) 12.2 (6.5) 11.1 (6.0) 3.48 0 .031
* Values transformed into logarithm for the statistical test.
Table 4 – Values   of the odds ratios and their 95% confidence intervals (95% CI) for Japanese-Brazilians according to the
ankle-brachial index and other variables (final and initial model).
Var iable Initial model Final model
P R 95% Ci P R 95% Ci
CRP < 1.1 mg/L 1 1
1.1 – 9.9 mg/L 0.97 0.55-1.72 1.04 0.61-1.78
Homocysteine < 15 mg/dL 1 1
> 15 mg/dL 1.51 0.73-3.15 1.52 0.73-3.15
Smoking No 1 1
Yes (past) 1.88 0.85-4.17 1.89 0.86-4.18
Yes (current) 4.45 1.62-12.24 4 .36 1.64-11.60
Age < 60 years 1 1
> 60 years 0.96 0.55-1.66 0.96 0.55-1.66
Gender Female 1 1
Male 0.45 0.21-0.94 0.50 0.25-0.99
Arterial hypertension No 1 1
Yes 2.20 1.24-3.91 2 .25 1.28-3.95




factors, such as smoking, changes in the concentrations
of total cholesterol, HDL-cholesterol, LDL-cholesterol,
triglycerides and blood glucose, blood pressure and BMI
in up to 78% of men and 67% of women 22. CRP therefore
participates in the atherosclerotic process; however, its
real role is still debatable, ie, if it is only a mediator of
disease severity or is causally associated with it.
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A cross-sectional study, “The Tsurugaya Project”,
similar to ours, also evaluating a population of Japanese
origin, noted that patients with higher levels of CRP showed
the lower ABI values (OR 2.10 [95% CI 1.13 3.88]),
independent of other cardiovascular risk factors 23.
Nevertheless, Wensley et al., in a meta-
analysis on levels of CRP and risk of coronary and cere-
bral disease that included 194,418 individuals, concluded
that the causal relationship between atherosclerosis and
CRP levels are unlikely. Although there is a linear
correlation between levels of CRP and atherosclerotic
disease, the relationship weakens sharply after adjusting
for other cardiovascular risk factors. According to these
authors, CRP may be related to the severity of
atherosclerotic disease 24.
Genetic epidemiology has assisted in obtaining
evidence about the involvement of CRP in atherosclerotic
disease. The concentration of CRP is a hereditary trait, and
there has already been identified the presence of
polymorphisms in the CRP gene capable of influencing the
circulating level of this protein. These findings open a new
research opportunity, since the random allocation of alleles
at conception allows a balanced distribution of confounding
factors between genotypes. Still, the genotype is not
influenced by the presence of disease, the genetic
associations then being protected from reverse causality 25.
Table 6 - Number and percentage of Japanese-Brazilians according to the values   of the ankle-brachial index and demographic,
anthropometric, clinical and biochemical variables.
Var iável Ankle-brachial Index p
<0,70 0,71-0,90 >0,90 Tota l Chi -square
 (%) (%) N (%) N (%)
Gender Female 2.1 20.5 77.4 565 (100) 1.83 0.401
 Male 1.7 17.5 80.8 473 (100)
Age <  60 years 1.0 16.8 82.2 619 (100) 13 .94 <0.001
> 60 years 3.3 22.7 74.0 419 (100)
Smoking1 Não 1.7 19.3 79.0 717 (100) 2.92 0.572
 Yes (past) 1.6 18.7 79.7 187 (100)
 Yes (current) 3.9 19.2 76.9 130 (100)
Abdominal obesity2 No 1.2 18.9 79.9 503 (100) 2.92 0.232
 Yes 2.6 19.4 78.0 532 (100)
Body mass index3 < 23 kg/m2 2.3 19.8 77.9 344 (100) 4.66 0.324
 23.0 a 24.9 kg/m2 1.3 22.8 75.9 237 (100)
 >  25 kg/m2 2.0 16.7 81.3 456 (100)
Hypertension No 0.5 17.3 82.2 567 (100) 16 .70 <0.001
 Yes 3.6 21.4 75.0 471 (100)
Glucose tolerance Normal - 13.8 86.2 58 (100) 15 .58 0 .016
 GJA 0.8        18.6 80.6 377 (100)
 TGD 1.3 23.3 75.4 240 (100)
 DM 3.9 18.0 78.1 362 (100)
Hypercholesterolemia No 2.6 18.1 79.3 392 (100) 1.66 0.437
 Yes 1.6 19.8 78.6 646 (100)
Low HDL No 1.9 19.0 79.1 909 (100) 0.23 0.891
 Yes 2.3 20.2 77.5 129 (100)
High LDL No 2.2 18.7 79.1 536 (100) 0.72 0.698
 Yes 1.6 19.7 78.7 502 (100)
Hypertriglyceridemia No 1.1 19.6 79.3 367 (100) 2.13 0.344
 Yes 2.4 18.9 78.7 671 (100)
CRP < 1.1 mg/L 2.2 17.5 80.3 509 (100) 2.03 0.362
 1.1 – 9.9 mg/L 1.7 20.8 77.5 529 (100)
Homocysteine4      < 15 mg/dL 2.1 17.9 80.0 700 (100) 5.54 0.063
      >15 mg/dL 2.5         26.9 70.6 119 (100)
1 Four individuals without information
2 WHR > 0.80 for women and > 0.90 for men
3 Three individuals excluded without information
4 One subject without information
5 Homocysteine available for 819 individuals
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With this objective, Zacho et al. studied the
evolution of 51,286 individuals with CRP genotypes
responsible for long-term maintenance of high plasma CRP
levels and the occurrence of coronary or cerebral disease.
They concluded that the polymorphism in the CRP gene
was associated with high CRP plasma levels, but not with
increased risk of coronary or cerebral ischemia 26. Other
studies evaluating the genetic epidemiology are consistent
with the absence of a causal relationship between
polymorphisms of the CRP gene with coronary disease 26-28.
In summary, the published genetic studies 24-28
were not able to assign a causal role of CRP in
atherosclerosis. The development of specific inhibitors for
CRP should be of great help to arrive at this answer. Under
development lies the 1,6 hexane-diphosphocholine, which
has a very short half-life 29. So far, the actual role of CRP in
atherosclerosis is controversial. According to Pepys, CRP is
present in atherosclerotic plaques, often collocated with
the elements of the complement. The presence at the cri-
me scene, however, is not necessarily evidence of guilt 30.
Our findings suggest that CRP is a marker of
severity or intensity of the disease. Since the CRP is released
in response to an inflammatory process in the plate, the
higher its value, the more intense the local inflammatory
reaction. As the intensity of the inflammatory response
corresponds to the intensity of atherosclerotic disease, the
measurement of CRP may assist in the mapping of patients,
identifying those that can evolve with worse prognosis.
R E S U M O
Objetivo: avaliar a relação entre a doença arterial obstrutiva periférica e níveis elevados de proteína C-reativa em população nipo-
brasileira de alto risco cardiovascular. Métodos: estudo transversal derivado de estudo de base populacional sobre a prevalência de
diabetes e doenças associadas em população nipo-brasileira. Mil trezentos e trinta indivíduos com idade >30 foram submetidos a
exame clínico e laboratorial, incluindo a dosagem da proteína C-reativa ultrassensível. O diagnóstico da doença arterial obstrutiva
periférica foi realizado através do cálculo do índice tornozelo-braço. Foram considerados portadores de doença arterial obstrutiva
periférica  os pacientes que apresentaram índice tornozelo-braço <0,9. Após aplicação dos critérios de exclusão, 1038 indivíduos
completaram o estudo. Resultados: a média de idade da população foi 56,8 anos, 46% pertencentes ao sexo masculino. A
prevalência da doença arterial obstrutiva periférica foi 21%, sem diferença entre os sexos. A análise dos dados não mostrou
associação entre doença arterial obstrutiva periférica e proteína C-reativa ultrassensível. Os pacientes com índice tornozelo-braço
<0,70 apresentaram valores mais elevados de proteína C-reativa ultrassensível e o pior perfil cardiometabólico. Encontramos
associação positiva e independente da doença arterial obstrutiva periférica com hipertensão arterial e tabagismo. Conclusão: a
associação encontrada entre valores baixos de índice tornozelo-braço e níveis elevados de proteína C-reativa ultrassensível pode
sugerir uma relação de gravidade auxiliando mapeamento dos pacientes de maior risco.
Descritores: Doença arterial periférica. Proteína C-reativa. Aterosclerose. Homocisteina.
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